Bank of America Corp DE Purchases New Holdings in Replimune Group, Inc. $REPL

Key Points

• Bank of America purchased 329,385 Replimune shares worth approximately $3.65 million, giving it a 0.39% stake. Institutional investors and hedge funds collectively own 92.53% of the company.
• Replimune shares opened at $13.00, up 3.5%, with a market capitalization of about $1.22 billion and a 52-week range of $1.50 to $16.33.
• Analysts maintain a consensus “Moderate Buy” rating with a $12.00 price target, despite the company missing quarterly EPS estimates ($0.72 loss versus a projected $0.69 loss).

Bank of America Corp DE purchased a new position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 329,385 shares of the company's stock, valued at approximately $3,646,000. Bank of America Corp DE owned 0.39% of Replimune Group as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in Replimune Group during the second quarter valued at about $99,171,000. Erste Asset Management GmbH raised its holdings in shares of Replimune Group by 30.1% in the 4th quarter. Erste Asset Management GmbH now owns 2,120,000 shares of the company's stock worth $20,619,000 after purchasing an additional 490,000 shares during the period. Commodore Capital LP acquired a new position in shares of Replimune Group in the 4th quarter valued at about $13,851,000. Dimensional Fund Advisors LP lifted its stake in shares of Replimune Group by 1.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,140,099 shares of the company's stock valued at $8,719,000 after purchasing an additional 20,742 shares in the last quarter. Finally, EcoR1 Capital LLC acquired a new position in shares of Replimune Group in the 1st quarter valued at about $7,650,000. Institutional investors and hedge funds own 92.53% of the company's stock.

Replimune Group Stock Up 3.5%

NASDAQ REPL opened at $13.00 on Wednesday. The stock has a market cap of $1.22 billion, a PE ratio of -4.13 and a beta of 0.94. Replimune Group, Inc. has a fifty-two week low of $1.50 and a fifty-two week high of $16.33. The business has a 50 day moving average price of $13.08 and a two-hundred day moving average price of $9.25. The company has a quick ratio of 5.23, a current ratio of 5.23 and a debt-to-equity ratio of 1.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.03). As a group, sell-side analysts predict that Replimune Group, Inc. will post -2.81 EPS for the current fiscal year.

Wall Street Analyst Weigh In

REPL has been the subject of a number of research analyst reports. Wolfe Research raised shares of Replimune Group to an "outperform" rating in a research report on Tuesday, August 4th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Replimune Group in a research report on Wednesday, August 12th. Wedbush upgraded shares of Replimune Group from a "neutral" rating to an "outperform" rating and set a $12.00 price objective for the company in a research note on Friday, August 7th. BMO Capital Markets raised shares of Replimune Group from an "underperform" rating to an "outperform" rating and set a $16.00 price objective for the company in a research report on Tuesday, June 30th. Finally, Weiss Ratings downgraded shares of Replimune Group from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $12.00.

Insider Activity

In other Replimune Group news, CFO Emily Hill sold 9,256 shares of the business's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $14.28, for a total value of $132,175.68. Following the transaction, the chief financial officer owned 215,852 shares in the company, valued at $3,082,366.56. The trade was a 4.11% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Andrew Schwendenman sold 7,632 shares of the firm's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $98,987.04. Following the sale, the chief accounting officer owned 99,425 shares of the company's stock, valued at $1,289,542.25. This represents a 7.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 79,124 shares of company stock worth $1,038,364. Corporate insiders own 5.40% of the company's stock.

About Replimune Group

Replimune Group, Inc is a biotechnology company focused on developing oncolytic immunotherapies designed to stimulate the immune system to recognize and attack cancer. The company's approach is based on a proprietary platform that uses genetically engineered herpes simplex virus type 1 (HSV-1) to selectively replicate in tumors and deliver immune-activating payloads.

Replimune's lead product candidate is RP1, also known as vusolimogene oderparepvec, an investigational oncolytic immunotherapy being evaluated in clinical studies for solid tumors, including melanoma and cutaneous squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.